Outcomes
treatment-related, Cancer
ADVERSE EVENT, RECURRENCE, METASTASIS, SECONDARY, CANCER
The primary end point was OS, and the secondary end points were progression-free survival (PFS), local-regional recurrence–free survival, distant metastasis–free survival, and treatment-related toxic effects. The time to each outcome was calculated from the date of randomization. All treatment-related toxic effects were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.